Abstract #3945

Diagnostic Consensus in the Interpretation of Ultra-High-Field MRS in Glioma Patients

Uzay E Emir^1,2, Jannie Wijnen³, Olaf E Ansorge⁴, Evita Wiegers³, Anja van der Kolk⁵, Alexander Lin⁶, and Clark Chen⁷

¹School of Health Sciences, Purdue University, West Lafayette, IN, United States, ²Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, United States, ³Radiology, University Medical Centre Utrecht, Utrecht, Netherlands, ⁴University of Oxford, Oxford, United Kingdom, ⁵Antoni van Leeuwenhoek Hospital, Netherlands Cancer Center, Amsterdam, Netherlands, ⁶Brigham and Women’s Hospital / Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States, ⁷Department of Neurosurgery, University of Minnesota, Minneapolis, MN, United States

We have recently initiated a 7T MRS glioma consortium, intending to bring together experts in the field to discuss pitfalls, promises, and potential research avenues of MRS in gliomas. During the "GlioMaRS-NET Workshop" in 2020, we tested the efficacy of UHF MRS for predicting the molecular characteristics by visual inspection by conducting a survey with a set of previously acquired UHF spectra from glioma patients. There was a high concordance in diagnostic interpretation of spectra for the identification of IDH-mutant gliomas versus IDH-wildtype gliomas.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.